Reference tracker zorato free#On the multivariable analysis, ATB emerged as a strong predictor of worse overall survival (OS) (HR=1.42 (95% CI 1.13 to 1.79) p=0.0024), and progression free survival (PFS) (HR=1.29 (95% CI 1.04 to 1.59) p=0.0192) in the pembrolizumab but not in the chemotherapy cohort. No association with clinical outcomes was found according to baseline statin, aspirin, β-blocker and metformin within the pembrolizumab cohort. Corticosteroid and proton pump inhibitor (PPI) therapy but not ATB therapy was associated with poorer performance status at baseline in both the cohorts. Results 950 and 595 patients were included in the pembrolizumab and chemotherapy cohorts, respectively.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |